Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...
APR Applied Pharma Research s.a.
Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa ("APR"), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for its investigational drug code-named APR-TD011 for treatment of ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - Patient safety in intensive care units could be significantly improved if false alarms could be greatly reduced and critical complications such as epileptic seizures could be predicted. This is where the "ICU Cockpit" project of the National Research Programme "Big Data" (NRP 75) comes in: The large amounts of data from intensive care medicine will be used to develop procedures for early warning systems and ...
London (ots/PRNewswire) - Senzer's pharmaceutical cannabinoid device has won another major design award, with the German Design Council commending the unique inhaler for having 'a clear modern design that perfectly combines ergonomics and functionality'. The award is the third design success for Senzer's Class IIa Medical Device, which is breath-activated and delivers ...
Zurich (ots) - The medication costs in Switzerland amounted to about CHF 7.6 billion in 2018. Since 2010, costs have risen by 46 percent, whereby half of this increase was attributable to immunosuppressants and cancer medication. Great savings potential is above all associated with the use of biosimilars. One of the other findings of this year's Helsana Drug Report is ...
Darmstadt, Germany (ots/PRNewswire) - - Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients in Japan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in ...
Dusseldorf, Germany (ots/PRNewswire) - - SQ Innovation and Gerresheimer sign partnership for micro pumps for heart failure treatment - Sanofi terminates development project for micro pumps for patients with diabetes - Further projects with pharma customers for various therapy areas for the micro pump started Sensile Medical, a subsidiary of Gerresheimer AG, has signed ...
Hitachi Medical Systems Europe Holding AG
Berlin (ots/PRNewswire) - 25th-26th November 2019, Berlin RESTORE-Health by Advanced Therapies invites you to join the First Advanced Therapies Science Meeting (ATSM), an EACCME® accredited event, which will be held at the Maritim Hotel, Stauffenbergstraße in Berlin from the 25th - 26th November 2019. Advanced Therapies are one of the most recent and significant advances in medicine. They include gene and cell therapies ...
Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen approved across all IMDC prognostic risk groups and ...
Barcelona, Spain (ots/PRNewswire) - An interactive exhibition celebrating the 50th anniversary since the completion of the first successful colonoscopy has been launched at the United European Gastroenterology (UEG) Week in Barcelona. The educational exhibition is jointly supported by Norgine, Fujifilm and Olympus ...
Amsterdam (ots/PRNewswire) - Norgine B.V. highlighted new data from a study supported by its partner company Shield Therapeutics, presented today at the United European Gastroenterology (UEG) Week in Barcelona showing that ferric maltol, a novel oral iron replacement therapy, was found to be non-inferior to ...
New 'Face up to rosacea' campaign comprising online content and a downloadable, personalized patient appointment guide, equips people living with the distressing skin disease to seek expert support to help break the cycle of rosacea and aim for long-term treatment success Lausanne, Switzerland (ots/PRNewswire) - ...
The International Osteoporosis Foundation (IOF)
Kfar Saba, Israel (ots/PRNewswire) - CartiHeal, developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the first implantation of the Agili-C(TM) implant, as part of Investigational Device Exemption (IDE) clinical study by Dr. ...
- One-year outcomes of real-world edoxaban-treated European patients from the Global ETNA-AF registry showed low rates of potentially life-threatening bleeding and low CV events in elderly NVAF patients1 - The Global ETNA-AF programme is currently the largest and most comprehensive repository of routine clinical ...
Lausanne (ots) - First patient enrolled in the investigator initiated CATRIPCA study (Combination with an IAP Antagonist To Reverse Immune resistance in Pancreatic and Colorectal Adenocarcinoma) at the Léon Bérard Cancer Center in Lyon France Debiopharm (www.debiopharm.com) announced today the first patient ...
Madrid (ots/PRNewswire) - QUANTIC NANOTECH (https://qnanotech.com/), a product division of Spanish DEMAC S.A. group who presented the first home wearable osteoarthritis treatment glove system "QNANO GLOVE (https://qnanotech.com/)" during the last CES 2019 Edition in Las Vegas, announced today the opening of free ...
Not intended for US, Canada and UK-based media Darmstadt, Germany, and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the ...
EASL European Association for the study of the Liver
Hong Kong (ots/PRNewswire) - OrbusNeich Medical K.K. of Tokyo Japan has announced that the Japan Ministry of Health, Labour, and Welfare (MHLW) has granted Shonin market approval for the COMBO Plus Coronary Stent. The COMBO Plus Coronary Stent is the first drug-eluting stent [DES] to combine the proprietary endothelial progenitor cell [EPC] capture technology with an ...
Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: 4062; 4934. - New subgroup analyses for ...
Cork, Ireland (ots/PRNewswire) - Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea. At a recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), Hovione ...
Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Darmstadt, Germany and ...
Barcelona, Spain (ots/PRNewswire) - According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes ...
London (ots/PRNewswire) - Senzer Pharmaceuticals has been granted a CE Mark that certifies its inhaler as a medical device, allowing it to now be available for patients in Europe for the 'safe and effective delivery of pharmaceutical cannabinoids.' The Class IIa Medical Device approval is the first-ever in the cannabinoid space and clears the way for the UK-based ...
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk announced today the results from two Ozempic® (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: - Ozempic® was superior to treatment with the SGLT-2 inhibitor canagliflozin (300 mg) in reducing HbA1c and ...
Barcelona, Spain (ots/PRNewswire) - Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA1c levels. Greater reductions in HbA1c were demonstrated with 7 ...
Bagsværd, Denmark (ots/PRNewswire) - New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (>=10 years of diagnosis) not optimally controlled on their current basal-bolus regimen, Fiasp® (fast-acting ...
Geneva (ots/PRNewswire) - Santen EMEA's significant expansion into the surgical devices arena is underlined by the company's activities at this year's European Society of Cataract and Refractive Surgeons (ESCRS) congress. In addition to the launch of a new monofocal, hydrophobic intraocular lens (IOL), xact(TM) ...